, Volume 72, Issue 14, pp 1929–1950 | Cite as


A Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin’s Lymphoma and Multiple Myeloma
Adis Drug Evaluation


Bendamustine (Levact®) is an alkylating agent consisting of three structural elements: a 2-chloroethylamine alkylating group; a butyric acid side chain; and a benzimidazole ring. Although its precise mechanism of action is as yet unknown, it appears to exert its antineoplastic effects via a different mechanism to those of other alkylating agents. This article reviews the utilization of intravenous bendamustine in patients with chronic lymphocytic leukaemia (CLL), rituximab-refractory indolent non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), focusing on indications for which the agent is approved in the EU.

As monotherapy, bendamustine was effective in the first-line treatment of adults with CLL, significantly prolonging progression-free survival (PFS) and improving the overall response (OR) rate after a median duration of follow-up of 35 months compared with chlorambucil in a randomized, open-label, multinational, phase III study. PFS and the OR rate were at least 2-fold greater with bendamustine than with chlorambucil when data from the overall patient population were stratified by Binet stage.

In the treatment of adults with rituximab-refractory indolent NHL, monotherapy with bendamustine was efficacious, with an OR achieved by at least three-quarters of patients in two noncomparative multicentre studies. Patients with follicular histology or those who had responded or were refractory to their previous chemotherapy regimen (including alkylator therapy) also appeared to respond to bendamustine monotherapy.

Front-line combination therapy with bendamustine plus prednisone was significantly more effective than combination therapy with melphalan plus prednisone in prolonging the time to treatment failure, according to a randomized, open-label multicentre, phase III study in adults with MM. Moreover, the benefits of bendamustine plus prednisone appeared to be maintained beyond 30 months, with a retrospective calculation of PFS demonstrating a borderline statistical significance in favour of bendamustine plus prednisone over melphalan plus prednisone.

The tolerability profile of bendamustine in adults with CLL, indolent NHL or MM was mostly consistent with the known toxicities of the agent, with adverse events often managed with dose modifications.

Although further data are required to fully establish the comparative efficacy of intravenous bendamustine in the management of CLL, rituximab-refractory indolent NHL or MM, it appears to be a useful addition to the armamentarium of currently available therapies for these haematological malignancies.


  1. 1.
    National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in haematological cancers [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/NICE_HAEMATOLOGICAL_CSG.pdf [Accessed 2012 Jul 27]
  2. 2.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin’s lymphomas. 3.2012 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf [Accessed 2012 Jul 27]
  3. 3.
    Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27 (9): 1492–501PubMedCrossRefGoogle Scholar
  4. 4.
    Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011; 71 (5): 625–49PubMedCrossRefGoogle Scholar
  5. 5.
    Napp Pharmaceuticals Limited. Levact 2.5mg/ml powder for concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/23469/SPC/Levact+2.5+mg+ml+powder+for+concentrate+for+solution+for+infusion/ [Accessed 2012 Jul 27]
  6. 6.
    Cephalon Inc. Treanda® (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022249s006lbl.pdf [Accessed 2012 Jul 27]
  7. 7.
    Barman Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61 (5): 631–8; discussion 639-40CrossRefGoogle Scholar
  8. 8.
    Plosker GL, Carter NJ. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma. Drugs 2008; 68 (18): 2645–60PubMedCrossRefGoogle Scholar
  9. 9.
    Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. Drugs 2010; 70 (13): 1703–18PubMedCrossRefGoogle Scholar
  10. 10.
    Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14 (1): 309–17PubMedCrossRefGoogle Scholar
  11. 11.
    Napp Pharmaceuticals Limited. Levact® i.v. (bendamustine HCl): product monograph [online]. Available from URL: http://www.napponcology.co.uk/_pdfs/Levact%20product%20monograph%20March%202011.pdf [Accessed 2012 Jul 27]Google Scholar
  12. 12.
    Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 2011; 48 (2 Suppl. 1): S12–23PubMedCrossRefGoogle Scholar
  13. 13.
    Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 2011; 48 (2 Suppl. 1): S4–11PubMedCrossRefGoogle Scholar
  14. 14.
    Beeharry N, Rattner JB, Bellacosa A, et al. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One 2012 Jun; 7 (6): e40342PubMedCrossRefGoogle Scholar
  15. 15.
    Roué G, López-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008 Nov; 14 (21): 6907–15PubMedCrossRefGoogle Scholar
  16. 16.
    Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759–70PubMedCrossRefGoogle Scholar
  17. 17.
    Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 2010; 66 (6): 1039–49PubMedCrossRefGoogle Scholar
  18. 18.
    Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010; 116 (1): 106–14PubMedGoogle Scholar
  19. 19.
    Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27 (26): 4378–84PubMedCrossRefGoogle Scholar
  20. 20.
    Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. Epub 2012 Aug 4Google Scholar
  21. 21.
    Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract no. 2367 plus poster]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  22. 22.
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun; 87 (12): 4990–7PubMedGoogle Scholar
  23. 23.
    Woods B, Hawkins N, Dunlop W, et al. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 2012; 15 (5): 759–70PubMedCrossRefGoogle Scholar
  24. 24.
    Holtzer-Goor K, Vandekerckhove S, van den Steen D, et al. Modelling the 10-year cost effectiveness of bendamustine as first line treatment for chronic lymphocytic leukaemia in the Netherlands [abstract no. 1089 plus poster]. Haematologica 2012 Jun; 97 Suppl. 1: 443Google Scholar
  25. 25.
    Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study [published erratum appears in J Clin Oncol 2008 Apr; 26 (11): 1911]. J Clin Oncol 2008 Jan; 26 (2): 204–10PubMedCrossRefGoogle Scholar
  26. 26.
    Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia 2010; 10 (6): 452–7CrossRefGoogle Scholar
  27. 27.
    Cheson BD, Friedberg JW, Kahl, BS, et al. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin’s lymphoma: a pooled analysis [poster no. II-657]. 51st American Society of Hematology Annual Meeting and Exposition; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  28. 28.
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 Apr; 17 (4): 1244–53Google Scholar
  29. 29.
    Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132 (4): 205–12PubMedCrossRefGoogle Scholar
  30. 30.
    Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975 Sep; 36 (3): 842–54PubMedCrossRefGoogle Scholar
  31. 31.
    Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer 1972 Aug; 30 (2): 382–9PubMedCrossRefGoogle Scholar
  32. 32.
    Peest D, Coldewey R, Deicher H, et al. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups. Eur J Cancer 1993; 29A (7): 978–83PubMedCrossRefGoogle Scholar
  33. 33.
    Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A (2): 146–51PubMedCrossRefGoogle Scholar
  34. 34.
    Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol 2009 Nov; 7 (11): 743–6PubMedGoogle Scholar
  35. 35.
    European Medicines Agency. Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5mg/ml, powder for concentrate for solution for infusion) [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Levact_29/WC500075906.pdf [Accessed 2012 Jul 27]
  36. 36.
    Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 Sep; 22 Suppl. 6: vi50-4Google Scholar
  37. 37.
    Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun; 111 (12): 5446–56PubMedCrossRefGoogle Scholar
  38. 38.
    Faderl S, Ferrajoli A, Frankfurt O, et al. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 2009 Mar; 23 (3): 457–66PubMedCrossRefGoogle Scholar
  39. 39.
    Cheson BD, Ashforth E. Newer strategies for overcoming rituximab resistance in non-Hodgkins lymphoma and chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009; 7 (2 Suppl. 5): 8–16Google Scholar
  40. 40.
    Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 Sep; 22 Suppl. 6: vi59–63PubMedCrossRefGoogle Scholar
  41. 41.
    European Medicines Agency. Levact. Article 29 referral. Annex I, II, III, IV [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Levact_29/WC500111589.pdf [Accessed 2012 Jul 27]
  42. 42.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. 1.2012 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf [Accessed 2012 Jul 27]
  43. 43.
    Harousseau J-L, Dreyling M. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v155–7PubMedCrossRefGoogle Scholar
  44. 44.
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) guideline on the evaluation of anticancer medicinal products in man [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500017748.pdf [Accessed 2012 Jul 27]
  45. 45.
    Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study [abstract no. 3]. J Clin Oncol 2012 Jun; 30 Suppl.Google Scholar
  46. 46.
    Cheson_BD, Wendtner C-M, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010 Feb; 10 (1): 21–7PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations